Katheriene Donovan
Managing Director, Fischer Labs Dana-Farber Cancer Institute
Seminars
Thursday 5th February 2026
Adopting Chemoproteomics Platforms to Inform Target Discovery & Drug Previously Undruggable Targets
10:00 am
- Developing a robust, high-throughput chemoproteomics platform to identify novel binding pockets, facilitate efficient target discovery, and drug orphan receptors
- Characterizing ligandable sites and binding pockets to unlock a plethora of novel target sites for hard-to-drug proteins
- Discussing data showing the unique benefit of applying chemoproteomics to transform target discovery and maximize time and cost-efficiency of R&D
